Analgesic efficacy of combined celiac and splanchnic nerve blocks in upper gastrointestinal tumours; A preliminary study

Phase 4

Completed

• Conditions: Patients suffer from visceral pain originating from in-operable abdominal cancer which originated from the upper abdominal viscera; Cancer - Pancreatic; Cancer - Biliary tree (gall bladder and bile duct); Anaesthesiology - Pain management

• Registration Number: ACTRN12614000410651
• Lead Sponsor: Mohamed Y. Makharita

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-04-15
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Patients suffer from visceral pain originating from in-operable abdominal cancer (originated from the upper abdominal viscera, from the stomach to the proximal transverse colon) reporting VAS equal to or greater than 7 after failure of strong opioids analgesics (3rd step of WHO analgesic ladder

Exclusion Criteria

Patients have INR >1.5 or platelet count <50,000,infection at the site of needle entry, persistent hypotension, ascites or whom receive previous neurolytic block or have psychiatric illness or whom declines to participate will be excluded from the study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Pain intensity was evaluated by visual analogue scale 0 – 10 (where 0 means no pain and 10 means the worst possible pain). <br>[At first visit (pre-enrollment), then every 2 weeks for one month and then monthly till patients' death.];Consumption of analgesics will be assessed by revision of participant medical records.[At first visit (pre-enrollment), then every 2 weeks for one month and then monthly till patients' death]

Secondary Outcome Measures

Name	Time	Method
Patient satisfaction will be assessed by using quality of life Questionnaire (QLQ- C30), [At first visit (pre-enrollment), then every 2 weeks for one month and then monthly till patients' death];Opioids side effects, including loss of appetite, nausea or vomiting, insomnia, constipation, urinary retention, pruritis will be evaluated. A score of 0–3 for each symptom (0, no symptom; 1, mild whereas no treatment was required; 2, moderate; 3, severe and intolerable) will be determined by each patient. [At first visit (pre-enrollment), then every 2 weeks for one month and then monthly till patients' death]